Sign In
Buy MYGN
$2.86
-2.51 (-46.74%)
At Close: Jul 31, 2026
Myriad Genetics (MYGN) Reports Break-Even Earnings for Q3
11:58pm, Monday, 03'rd Nov 2025
Myriad Genetics (MYGN) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.06 per share a year ago.
Highl ights Third quarter 2025 revenue of $205.7 million decreased by 4% year-over-year but was flat when excluding previously discussed headwinds 1 of $8.1 million , consistent with management expect
Myriad Genetics, Inc. $MYGN Stock Position Raised by Cwm LLC
04:07am, Saturday, 01'st Nov 2025
Cwm LLC lifted its stake in shares of Myriad Genetics, Inc. (NASDAQ: MYGN) by 148.3% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange C
Faster initial remission and response, persistent benefit over six months Faster initial remission and response, persistent benefit over six months
Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025
04:15pm, Monday, 27'th Oct 2025
SALT LAKE CITY, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its third quarter 2025 earnings confe
Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel
08:00am, Tuesday, 14'th Oct 2025
The Foresight® Carrier Screen includes all conditions recommended by the American College of Medical Genetics and Genomics recommendations The Foresight® Carrier Screen includes all conditions recom
Breast Cancer Awareness Month: Patient and Clinician Share Insights on how to tackle the fear of cancer screenings on YourUpdateTV
05:21pm, Wednesday, 08'th Oct 2025
Data Shows Misconceptions Fuel Cancer Fears but Genetic Testing Can Help New Myriad Genetics Cancer Risk Survey shows that more than half of women at high-risk for hereditary cancer would feel "empowe
Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy
08:01am, Tuesday, 23'rd Sep 2025
SALT LAKE CITY and BOSTON , Sept. 23, 2025 /PRNewswire/ -- Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (Nasdaq: SOPH), an AI
Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy
08:00am, Tuesday, 23'rd Sep 2025
SALT LAKE CITY and BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (Nasdaq: SOPH), an AI
Is it a Prudent Move to Retain MYGN Stock in Your Portfolio Now?
09:21am, Tuesday, 16'th Sep 2025
Myriad Genetics expands oncology testing and launches new diagnostics, but inflation and rising competition weigh on its outlook.
Myriad Genetics, Inc. (MYGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
11:06am, Wednesday, 10'th Sep 2025
Myriad Genetics, Inc. (NASDAQ:MYGN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 7:45 AM EDT Company Participants Samraat Raha - President, CEO & Director Ben Wheeler -
MYGN's GeneSight Test Proven Superior to TAU: Stock to Gain?
12:06pm, Friday, 05'th Sep 2025
Myriad Genetics' GeneSight test outperforms treatment-as-usual in major depression, raising hopes for broader adoption and renewed stock momentum.
Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology
07:00pm, Thursday, 04'th Sep 2025
SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced The Lancet Oncology published
SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
04:05pm, Wednesday, 27'th Aug 2025
SALT LAKE CITY, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will particip
